TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20831698
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d.
Study: 10651664
Drug: OAC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole 20 mg b.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Study: 10215733
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy (quadruple regimen: omeprazole 20 mg b.d., tripotassium dicitrato bismuthate 120 mg q.d.s., tetracycline 500 mg q.d.s., metronidazole 400 mg t.d.s.)
Study: 10215733
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy (2-week proton pump inhibitor-based triple therapy)
Study: 10215733
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy (1-week proton pump inhibitor-based triple therapy)
Study: 25496052
Drug: Interactive balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive balance training program (4 weeks, twice a week) with wearable sensors providing visual/auditory feedback
Study: 17709294
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BoNT-A) treatment
Study: 10361663
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intrathecal morphine sulfate
Study: 10361663
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intrathecal morphine sulfate
Study: 10361663
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intrathecal morphine sulfate
Study: 7572762
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin plus penicillin V (group A)
Study: 3093827
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg at night)
Study: 27714506
Drug: Intermittent balneological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent balneological treatment for 5 weeks (10 sessions of hydrotherapy and mud pack therapy)
Study: 15825711
Drug: FGF 2
Normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 2 l.min(‐1)
Study: 15825711
Drug: FGF 1
Normalized name: Fibroblast Growth Factor 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 1 l.min(‐1)
Study: 9613912
Drug: Nebulized budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized budesonide, 2 mg
Study: 3516755
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sodium diclofenac tablet (Novapirina) every 12 hours for 2 consecutive days
Study: 3516755
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet of acetylsalicylic acid (Aspirin) every 8 hours for 2 consecutive days
Study: 22357185
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IG)
Study: 29502065
Drug: Tracheal intubation
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracheal intubation with 1.5 mg/kg propofol and 1 µg/kg remifentanil, followed by 0.9 mg/kg rocuronium
Study: 15659242
Drug: Rivastigmine high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine high-dose therapy
Study: 12516679
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B 3D Excel (PTB1)
Study: 12516679
Drug: Increased toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased toothbrush force from 90 g to 150 g
Study: 2102705
Drug: 4-carbomethoxythiazolidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-carbomethoxythiazolidine 400 mg/d
Study: 2102705
Drug: 4-carbomethoxythiazolidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-carbomethoxythiazolidine 600 mg/d
Study: 2102705
Drug: 4-carbomethoxythiazolidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-carbomethoxythiazolidine 200 mg/d (three times a day)
Study: 21788433
Drug: Unshorn sheep
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unshorn sheep (treatment group)
Study: 21788433
Drug: Post-shearing (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-shearing (treatment group)
Study: 26421525
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser treatment
Study: 14992903
Drug: Pexelizumab (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg/h infusion for 24 hours)
Study: 11720319
Drug: Metronidazole 20
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 20 mg/kg/d for 2 weeks (n = 9)
Study: 9385282
Drug: Nasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal calcitonin 200 IU per day, divided in 2 doses
Study: 23464664
Drug: Teneligliptin 40
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 40 mg
Study: 15708690
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules per day)
Study: 23881337
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy
Study: 11579192
Drug: Both antipsychotic
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antipsychotic medication and behavioural therapy
Study: 3450522
Drug: Nitrendipine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (twice daily)
Study: 3450522
Drug: Nitrendipine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (once daily)
Study: 29373235
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg per day for 3 days)
Study: 27825313
Drug: Pharmacist medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist medication therapy management (MTM)
Study: 25693889
Drug: S(+)‐ketamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine at 120 ng/mL and 240 ng/mL
Study: 23669628
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (4 mg/day)
Study: 23669628
Drug: Low-dose folic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose folic acid (0.4 mg/day)
Study: 19032127
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy
Study: 21679353
Drug: Conventional best
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional best standard treatment (CBST)
Study: 12890205
Drug: 20% DFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% DFO in aqueous cream
Study: 10702175
Drug: Carotenoid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid supplement (25 mg total carotenoids/d)
Study: 10702175
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carotenoids and vitamin E (335 mg RRR-alpha-tocopherol/d)
Study: 6367415
Drug: Gallopamil 150
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 150 mg/day
Study: 17526166
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (control group)
Study: 15657021
Drug: Self-Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Monitoring of Blood Glucose (SMBG) + Hypoglycemia Anticipation, Awareness and Treatment Training (HAATT)
Study: 23591599
Drug: Vedolizumab 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 2, 6, or 10 mg/kg on days 1, 15, and 43, followed by maintenance dosing every 8 weeks
Study: 16205924
Drug: 9NC administered
Normalized name: 9NC
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9NC administered with food (standard meal)
Study: 16205924
Drug: 9NC administered
Normalized name: 9NC
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9NC administered under fasting conditions
Study: 16205924
Drug: 9AC administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9AC administered with food (standard meal)
Study: 16205924
Drug: 9AC administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9AC administered under fasting conditions
Study: 18414916
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg morphine
Study: 12666001
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg morphine + 50 microg clonidine
Study: 12666001
Drug: Clonidine (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (combined with morphine)
Study: 9773721
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (Humulin R)
Study: 2953174
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.04 microgram/kg/min) in hypertensive men (n = 13)
Study: 19469799
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg GTPs twice daily
Study: 19469799
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg GTPs
Study: 8268525
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (50 mg/kg administered just before and after CPB, and every 90 minutes during CPB)
Study: 22381987
Drug: Computerized insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized insulin dose calculator
Study: 10478579
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion with normal saline
Study: 21399902
Drug: Clonidine 0.1
Normalized name: clonidine 0.17 MG
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 0.1 mg
Study: 6311306
Drug: Nabilone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (3 mg orally three times a day, starting the day before cis-platinum and ending the day after)
Study: 6311306
Drug: Chlorpromazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (12.5 mg IM, 15 minutes before cis-platinum)
Study: 21813629
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg at induction followed by 0.3 mg/kg/h infusion)
Study: 10529580
Drug: Kneippism (custom‐tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kneippism (custom‐tailored combination of therapies comprising hydrotherapy, kinesiotherapy, phytotherapy, dietetics, 'ordnungstherapie', and continued disease‐specific standard treatment)
Study: 6978270
Drug: Indoprofen 800
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 800 mg daily
Study: 790553
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg daily
Study: 31896686
Drug: Chlorambucil or
Normalized name: chlorambucil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil or rituximab or chlorambucil plus rituximab (systemic treatment)
Study: 31242926
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment and rehabilitation
Study: 31650182
Drug: Elagolix 100
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix 100 mg BID
Study: 31654294
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg BID
Study: 22646157
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily (loading dose 300 mg) plus indobufen 100 mg twice a day (group A)
Study: 22646157
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily after 300 mg loading dose (group B)
Study: 6751116
Drug: Praziquantel 60
Normalized name: praziquantel 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 60 mg/kg body weight in three divided doses orally
Study: 30537752
Drug: Virtual Reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality-based Tai Chi (VRTC) exercise program, conducted twice weekly for 6 months
Study: 24628747
Drug: Hydrocodone/acetaminophen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen (5 mg/500 mg)
Study: 24628747
Drug: Codeine/acetaminophen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/acetaminophen (30 mg/300 mg)
Study: 1928881
Drug: Hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen
Study: 24186866
Drug: Metformin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2,000 mg/day)
Study: 12107206
Drug: im T
Normalized name: Trimethoprim Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: im T enanthate 100 mg/wk plus daily oral placebo (T)
Study: 12107206
Drug: im placebo/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: im placebo/wk plus 125 microg daily oral levonorgestrel (LNG)
Study: 10053098
Drug: rhuIL‐6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuIL‐6 plus G‐CSF
Study: 8821076
Drug: Infusion-capsule
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion-capsule
Study: 8821076
Drug: Infusion-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion-infusion
Study: 2286454
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 g p.o. each on the evening before and after the operation)
Study: 25528977
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of health worker training, adolescent-friendly facility improvements, and broad information dissemination via community, schools, and mass media.
Study: 25696357
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice-daily plus dietary counselling
Study: 9773735
Drug: Pre‐lunch reduced‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐lunch reduced‐dose lispro (70%) before lunch and supper with supplemental lunchtime NPH and with a 6‐h interval until dinner
Study: 9773735
Drug: Pre‐lunch reduced‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐lunch reduced‐dose lispro (70%) before lunch and supper with supplemental lunchtime NPH and with a 8‐h interval until dinner
Study: 9773735
Drug: Usual‐dose lispro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual‐dose lispro alone
Study: 7752178
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 or 100 mg/day)
Study: 3136828
Drug: Single instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single instillation of 40 mg mitomycin C in 40 ml of water
Study: 28657529
Drug: D-002 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002 (50 mg once daily for 12 weeks)
Study: 28657529
Drug: GS/CS (375/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS/CS (375/300 mg once daily for 12 weeks)
Study: 25555621
Drug: BNT+placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT+placebo injection
Study: 25555621
Drug: CE+placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE+placebo injection
Study: 12544677
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (equine conjugated estrogens 0.625 mg/day + dydrogesterone 5 mg/day in a continuous combined regimen)
Study: 12544677
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with hormones)
Study: 29936125
Drug: Positive psychotherapy
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive psychotherapy for smoking cessation with transdermal nicotine patch and text messaging support
Study: 29936125
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral smoking cessation counseling with transdermal nicotine patch and text messaging support
Study: 26183669
Drug: Electronic daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic daily diary incorporating VVSymQ® instrument
Study: 24528569
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (two sequential face-to-face consultations)
Study: 18246681
Drug: Guipi Wan
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guipi Wan (Pill for Invigorating the Spleen and Nourishing the Heart)
Study: 15046708
Drug: Metalloproteinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metalloproteinase inhibitors
Study: 26978413
Drug: meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 15 mg/day
Study: 22455403
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil on-demand exclusively
Study: 17559108
Drug: Drug-eluting nitinol
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting nitinol stents
Study: 10868163
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments
Study: 23474270
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily energy intake
Study: 88853
Drug: Bleomycin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin therapy
Study: 88853
Drug: Cryo-surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo-surgical treatment
Study: 20522841
Drug: Indacaterol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (both doses)
Study: 6829517
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific pharmacotherapy
Study: 21719165
Drug: Standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose infusion (SG; 5.0 mg kg(‐1) min(‐1))
Study: 18329563
Drug: Propranolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (30 mg)
Study: 16401810
Drug: Emtricitabine 200
Normalized name: emtricitabine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine 200 mg once daily for 48 weeks
Study: 15536785
Drug: Locally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally delivered minocycline microspheres (Arestin) as an adjunct to scaling and root planing (SRP)
Study: 3521401
Drug: Ethaverine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethaverine 200 mg four times daily
Study: 17534380
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg nicotine
Study: 17534380
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nicotine
Study: 24884787
Drug: Sitagliptin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin treatment (n=16)
Study: 24884787
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Control, n=10)
Study: 22261813
Drug: Early passive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early passive therapy followed by active robot‐assisted intervention (HTI group, 10 sessions of passive therapy followed by 10 sessions of active therapy)
Study: 10851101
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (4-week program focusing on strength and endurance of back and abdominal muscles)
Study: 8671131
Drug: Electromagnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic therapy at 800 Hz
Study: 8671131
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy or treatment with 600 Hz
Study: 29745007
Drug: ASP0113 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP0113 (5 mg, 5 doses on Days 30/60/90/120/180 posttransplant)
Study: 24718775
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral melatonin
Study: 23302558
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine antibiotics treatment)
Study: 8927671
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine daily
Study: 14714120
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluoxetine daily
Study: 14714120
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine once every third day
Study: 12172973
Drug: Heptaplatin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptaplatin 400 mg/m(2) i.v. over 1 h on day 1 plus 5‐fluorouracil (5‐FU) 1000 mg/m(2) per day continuous i.v. from day 1 to day 5
Study: 11533324
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus acetazolamide and furosemide
Study: 2196030
Drug: Curosurf (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf (200 mg/kg) given intratracheally
Study: 6315123
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone 200 mg daily
Study: 6315123
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone 300 mg daily
Study: 6315123
Drug: Conjugated oestrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated oestrogens 1.25 mg daily
Study: 30558672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no spacer injection)